Study of CGC-11047 (PG-11047) in Subjects With Advanced Refractory Solid Tumors

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Progen Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT00705653
First received: June 23, 2008
Last updated: March 21, 2012
Last verified: March 2012
  Purpose

This phase I study aims to assess the safety and tolerability of a new drug - PG-11047 - and to establish what happens to the drug once inside the body. An escalating dose of PG-11047 will be investigated in this study and the maximum tolerated dose of the drug will be established.


Condition Intervention Phase
Cancer
Drug: PG-11047
Phase 1

Study Type: Interventional
Study Design: Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I Study of CGC-11047 in Subjects With Advanced Refractory Solid Tumors

Resource links provided by NLM:


Further study details as provided by Progen Pharmaceuticals:

Primary Outcome Measures:
  • Maximum Tolerated Dose (MTD) [ Time Frame: The MTD had to occur during cycle 1 of treatment ] [ Designated as safety issue: Yes ]

    The MTD was defined as the dose below one-third of at least 6 subjects (e.g., 2/6, 3/9, 4/12) experienced a Dose-limiting toxicity (DLT).

    Dose-limiting toxicities (DLTs) used to determine the MTD had to occur during cycle 1 of treatment and had to be considered related to PG-11047.



Secondary Outcome Measures:
  • Preliminary Efficacy [ Time Frame: For the purposes of this study, patients were reevaluated radiologically every 8 weeks. In addition to a baseline scan, confirmatory scans were obtained 6-8 weeks following initial documentation of an objective response, when appropriate. ] [ Designated as safety issue: Yes ]
    As per RECIST Criteria (V 1.0) by radiologic evaluations: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR) >= 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD; Progressive Disease (PD), >= 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions; Stable Disease (SD), neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.


Enrollment: 46
Study Start Date: March 2005
Study Completion Date: August 2009
Primary Completion Date: August 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: PG-11047 Drug: PG-11047
PG-11047 will be administered as a 60-minute intravenous infusion on days 1, 8 and 15 of each 28 day cycle. A treatment cycle will be defined as 4 weeks of therapy. The planned minimum treatment schedule is 2 cycles of PG-11047 treatment (8 weeks).

Detailed Description:

This is an open-label phase I, dose-escalation safety study in subjects with refractory solid tumors. The primary objectives of the study are to assess the safety, tolerability, and pharmacokinetics of PG-11047. PG-11047 will be administered as a 60-minute intravenous infusion on days 1, 8 and 15 of each 28 day cycle. The planned minimum treatment schedule is 2 cycles (8 weeks) of PG-11047 treatment. Subjects who tolerate treatment may be eligible to receive additional cycles as per investigator's medical judgment. Evaluation of anti-tumor response will be performed every 2 cycles.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • non-hematological malignancy where standard therapeutic measures do not exist or no longer effective.
  • ECOG - 0-2.
  • Life expectancy > 3 months.

Exclusion Criteria:

  • chemotherapy or radiotherapy within 4 weeks prior to entering the study.
  • previous high-dose chemotherapy with autologous allogeneic hematopoietic stem cell transplantation.
  • primary brain tumors or active brain metastases
  • history of significant or symptomatic cardiac arrhythmia, prior myocardial infarction or evidence of a current significant ventricular conduction abnormality
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00705653

Locations
United States, Illinois
University of Chicago, Cancer Research Centre
Chicago, Illinois, United States, 60637
Sponsors and Collaborators
Progen Pharmaceuticals
Investigators
Principal Investigator: Mark Ratain, M.D. University of Chicago
  More Information

Additional Information:
No publications provided

Responsible Party: Progen Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00705653     History of Changes
Other Study ID Numbers: 47-01-001
Study First Received: June 23, 2008
Results First Received: November 6, 2011
Last Updated: March 21, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by Progen Pharmaceuticals:
cancer
advanced cancer
solid tumors
CGC-11047
PG-11047

ClinicalTrials.gov processed this record on August 19, 2014